Search results
Results from the WOW.Com Content Network
Atomoxetine is sometimes used in the treatment of cognitive impairment and frontal lobe symptoms due to conditions like traumatic brain injury (TBI). [48] [49] It is used to treat ADHD-like symptoms such as sustained attentional problems, disinhibition, [50] lack of arousal, fatigue, and depression, including symptoms from cognitive disengagement syndrome. [48]
If symptoms of discontinuation are severe, or do not respond to symptom management, the antidepressant can be reinstated and then withdrawn more cautiously, or by switching to a drug with a longer half life (e.g., fluoxetine), and then tapering and discontinuing that drug. [21] In severe cases, hospitalization may be required. [2]
Initial Symptoms Blister Agents Lewisite Gas: colorless Odor: geraniums Seconds to minutes Eye irritation, coughing, sneezing, and vomiting Mustard Gas: colorless Odor: horseradish, onions, or garlic; or fishy, musty, soapy, or almonds Minutes to hours Burning eyes, eyelid swelling, repeated blinking, sneezing, nasal secretion, sore throat, and
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.
[31] [32] Atomoxetine (Strattera) is another potent and selective NRI which is also effective and well tolerated treatment for adults with ADHD. This drug was the first ADHD treatment to be specially approved for adult use. Studies showed that atomoxetine is a nonstimulant and carries negligible risk of abuse.
The half-life of desvenlafaxine is about 11 hours, and steady-state concentrations are achieved after 4 to 5 days. [58] The half-life of duloxetine is about 12 hours (range: 8–17 hours), and steady-state is achieved after about 3 days. [11] Milnacipran has a half-life of about 6 to 8 hours, and steady-state levels are reached within 36 to 48 ...
In April 2014, The New York Times reported that sluggish cognitive tempo is the subject of pharmaceutical company clinical drug trials, including ones by Eli Lilly that proposed that one of its biggest-selling drugs, Strattera, could be prescribed to treat proposed symptoms of sluggish cognitive tempo. [57]
Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD Suboxone ( buprenorphine/naloxone ) - a partial opioid agonist used in the treatment of opioid use disorder T